Focus: Processa Pharmaceuticals is a public small-molecule biotech focused on oncology and rare diseases, headquartered in Vero Beach, Florida. The company operates at an early-stage with a pre-commercial pipeline and minimal cash reserves.
Profile data last refreshed 4h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Processa Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Processa Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Processa Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Processa Pharmaceuticals Inc. (PCSA) Peer Comparison – Compare with Others - Value Research
Processa Pharmaceuticals Inc. (PCSA) Peer Comparison – Compare with Others Value Research
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences - Yahoo Finance
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences Yahoo Finance
Processa Pharmaceuticals (PCSA) Slips 12% as Biotech Volatility Persists - Linear Regression - vinanet.vn
Processa Pharmaceuticals (PCSA) Slips 12% as Biotech Volatility Persists - Linear Regression vinanet.vn
Processa Pharmaceuticals (NASDAQ: PCSA) gains new 5.8% owner with no sole control - Stock Titan
Processa Pharmaceuticals (NASDAQ: PCSA) gains new 5.8% owner with no sole control Stock Titan
Processa Pharmaceuticals (PCSA) Slips 2.34% to $2.5 as Support at $2.38 Comes into Focus - Percent Above MA - vinanet.vn
Processa Pharmaceuticals (PCSA) Slips 2.34% to $2.5 as Support at $2.38 Comes into Focus - Percent Above MA vinanet.vn
M&A Roundup: Johnson & Johnson Collaborates with Sail Biomedicines, Processa Pharmaceuticals Acquires Vidya Therapeutics, Relation Collaborates with GSK - Pharmaceutical Executive
M&A Roundup: Johnson & Johnson Collaborates with Sail Biomedicines, Processa Pharmaceuticals Acquires Vidya Therapeutics, Relation Collaborates with GSK Pharmaceutical Executive
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo